Redx Pharma Phase I trial resumed

REDX is a clinical-stage R&D company focused on drugs targeting oncology and fibrotic disease. 2018 was a year that reset the benchmarks – new management team, restructured organisation focused on two therapeutic areas, and a clean balance sheet. 2019 will be characterised by a number of major milestones, including the recent restart of the Phase I/IIa trial with RXC004 with a revised protocol, and we note that RXC006 has been nominated as the first development candidate in the anti-fibrotic programme. Meanwhile, operating costs have been reduced while management considers all options available to strengthen its balance sheet.

  • Strategy: REDX is focused on the discovery and early clinical development of small molecule therapeutics in oncology and fibrotic disease. Its strategy is to develop assets through proof-of-concept clinical trials and then partner them for late-stage development and commercialisation.
  • Interims: REDX took the opportunity provided by its interim results to update the market on the advancement of its pipeline and financial position. The main news is the start of the trial with RXC004 with a revised protocol. REDX has also announced a £2.5m short-term loan. Net cash at 31 March was £3.3m.
  • Trial re-started: The Phase I trial with a reformulation of the porcupine inhibitor RXC004 has been resumed using a revised protocol, and REDX has indicated that the first patient has initiated, and additional patients are planned for enrolment. Initial safety and tolerability results are anticipated in 2H’19.
  • Risks: REDX has emerged from fiscal 2018 in a clean position with a focused strategy. The company has limited cash resources, boosted by a short-term shareholder loan, while it continues to explore the long-term funding of the group to advance the proof-of-concept trials for its development programmes.
  • Investment summary: The business plan focuses cash resources on progressing its drug leads in oncology and fibrotic disease to proof-of-concept early clinical development. Big pharma has been shown to pay substantial prices for good science and novel and/or de-risked assets with clinical data, reinforcing REDX’s strategy, potentially generating good returns and enhancing shareholder value.

DOWNLOAD THE FULL REPORT

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    REDX Pharma RXC006: first anti-fibrosis development candidate

    REDX Pharma (LON:REDX) is a clinical-stage biotechnology company focused on drugs targeting oncology and fibrotic diseases. An extensive review, led by the new CEO, has reinforced the vision of a streamlined pipeline in these two disease

    Hardman & Co

    Redx Pharma Streamlined, focused and good value

    Redx Pharma (LON:REDX) is a clinical-stage R&D company focused on drugs targeting oncology and fibrotic disease. 2018 was a year that reset the benchmarks – new management team, restructured organisation focused on two therapeutic areas, and

    Hardman & Co

    REDX Pharma ROCK2 inhibitors in chronic kidney disease

    REDX Pharma (LON:REDX)  new management team is continuing to focus its financial resources on progressing lead candidates in oncology and fibrotic disease into the clinic. An extensive internal review, led by the new CEO Lisa Anson

    Hardman & Co

    Redx Pharma Back to the clinic

    Redx Pharma Plc (LON:REDX) new management team is continuing to focus its financial resources on progressing its lead candidates in oncology and fibrotic disease into the clinic. When the first patient was treated with RXC004, its

    Hardman & Co

    Redx Pharma Clinical and corporate update

    The new management team of Redx Pharma Plc (LON:REDX) is focusing its financial resources (ca.£10m) on progressing its lead candidates in oncology and fibrotic disease into the clinic. Although the first patient was treated recently in

    Hardman & Co

    Redx Pharma Streamlined and clean

    Redx Pharma Plc (LON:REDX) has emerged from administration with a refocused R&D pipeline and in a very clean financial state with £13.6m net cash in the bank. The group’s strategy has been validated by the successful

    Hardman & Co

    Redx Pharma Plc CARB-X – new strategic collaboration

    Although Redx Pharma Plc (LON:REDX) has only been operational since late-2010, it has already discovered several valuable drug candidates, the first of which is about to begin clinical trials. Although management is focusing resources on the

    Hardman & Co

    Redx Pharma Plc RXC005 BTK inhibitor – watch this space

    Although Redx Pharma Plc (LON:REDX) has only been in operation since late-2010, it has already created several valuable drug candidates that are about to begin clinical development. Progress into the clinic will enhance significantly the value

    Hardman & Co

    Redx Pharma Plc Porcupine inhibitor enhances anti-PD-1 effect

    Although Redx Pharma Plc (LON:REDX) has only been in operation since late-2010, it has already created several valuable drug candidates that are about to begin clinical development. Progress into the clinic will enhance significantly the value

    Hardman & Co

    Redx Pharma Plc Advancing to clinic, increasing value

    Although Redx Pharma Plc (LON:REDX) has only been in operation since late-2010, it has already created several valuable drug candidates that are about to begin clinical development. Progress into the clinic will enhance significantly the value